GET DAILY SIGNALSOrthoPediatrics (KIDS) vs DENTSPLY Sirona (XRAY): Growth Momentum Meets Turnaround Efforts
Key Takeaways
- OrthoPediatrics (KIDS) is a pediatric orthopedic device specialist posting double-digit revenue growth and rising guidance, while DENTSPLY Sirona (XRAY) is a global dental equipment and consumables maker working through a turnaround marked by softer growth and leadership transitions.
- Tickeron AI Verdict: KIDS. Trend consistency, stronger relative momentum, and an improving profitability and cash-flow trajectory currently favor OrthoPediatrics over DENTSPLY Sirona in this head-to-head stock comparison.
- KIDS recently raised its full-year revenue outlook and moved toward free-cash-flow break-even, whereas XRAY's market positioning reflects reduced guidance and tempered analyst expectations.
- Sentiment diverges sharply: sell-side consensus on KIDS skews "Buy," while XRAY carries a "Hold" consensus amid a multi-month share-price slide.
- For more context on each name, explore KIDS Major News and KIDS Today's Price Move, along with XRAY Major News and XRAY Today's Price Move.
- Explore Trending AI Robots to see which automated trading strategies are currently favored by Tickeron's AI.
Setting the Stage for Two Distinct Healthcare Stories
Both KIDS and XRAY operate in the healthcare and medical-technology space, yet they sit at very different stages of their growth and profitability cycles. OrthoPediatrics is a focused pediatric orthopedics pure-play benefiting from durable procedure demand and a pipeline of new product launches, while DENTSPLY Sirona is a much larger dental equipment and consumables leader navigating restructuring, distribution realignment, and leadership change. This comparison is most relevant to investors and traders evaluating relative performance and market positioning between a high-growth specialty-device story and a value-oriented turnaround. Understanding the contrast in momentum, catalysts, and risk can help clarify which name offers the more favorable setup in the current market environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
OrthoPediatrics (KIDS): Building on Strong Fundamentals
KIDS, or OrthoPediatrics Corp., designs and sells anatomically appropriate implants, instruments, and specialty bracing exclusively for children with orthopedic conditions. Because the procedures it supports are generally non-elective, demand tends to be more stable than in consumer-discretionary healthcare categories. Recent market activity has rewarded this positioning: the stock has gained roughly 18% over the past three months and approximately 41% over the trailing year, climbing toward the upper end of its 52-week range.
The catalyst behind this strength has been fundamentals. In its most recent quarter, OrthoPediatrics reported revenue of about $72.7 million, up 19% year over year, and raised its full-year revenue guidance to a range of $270 million to $273 million, implying 14% to 16% growth. Management highlighted strong procedure volumes, record adjusted EBITDA, and a move to positive free cash flow. A multi-year "product launch super cycle" in trauma, deformity, and scoliosis remains in its early stages, giving analysts a basis for their broadly positive, "Buy"-leaning ratings and recently raised price targets.
DENTSPLY Sirona (XRAY): Working Through a Reset
XRAY, or DENTSPLY Sirona Inc., is among the world's largest manufacturers of professional dental equipment, consumables, and digital dentistry technology. In contrast to KIDS, the company is navigating a reset: recent quarters have featured softer earnings, reduced guidance, and ongoing leadership turnover, while a multi-year revenue trend has been broadly flat to slightly down. The stock has pulled back sharply in recent weeks, with a roughly 20% to 25% decline over the trailing 30 days and a one-year total return that remains negative.
Offsetting some of this pressure, management has been actively broadening its distribution footprint, including an expanded relationship with Midwest Dental that extends a historically consumables-focused partnership into the company's full digital-technology portfolio. The company also pays a quarterly dividend, which can appeal to income-oriented investors. Nevertheless, analysts have trimmed price targets and generally maintain a "Hold" consensus, reflecting caution around the timing of any margin and growth recovery. The shares trade near the low end of their 52-week range, signaling persistent investor skepticism about the pace of the turnaround.
Head-to-Head: Contrasting Trajectories
The most striking contrast between these two names is trajectory. KIDS is in a growth-and-inflection phase: revenue is expanding at a mid-to-high-teens rate, profitability metrics are improving, and free cash flow has turned positive. Its risk profile centers on execution—delivering on the product-launch "super cycle" and converting top-line growth into sustained profitability while managing a still-negative GAAP bottom line.
XRAY, by comparison, offers scale, an established global franchise, and a dividend, but carries a more challenged growth profile. Its trade-offs involve a turnaround dependent on cost discipline, distribution resets, and regaining share in a fragmented, increasingly competitive digital-dentistry market. Sector exposure also differs: KIDS concentrates in pediatric orthopedics with limited direct competition, while XRAY spans a broader, more competitive dental ecosystem subject to elective-procedure sensitivity and tariff-related cost pressures. In terms of market sentiment, the gap is wide—one stock is seeing raised targets and buy-side enthusiasm, while the other is absorbing downgrades and price-target reductions. From what I see, this divergence stands out clearly in the data.
Tickeron AI Verdict on the Comparison
Based on observable trend data, relative momentum, and fundamental positioning, Tickeron's AI currently favors KIDS over XRAY. OrthoPediatrics presents the more consistent trend structure: rising revenue, improved adjusted EBITDA, positive free cash flow, and upward guidance revisions, all of which align with the stock's recent relative strength. DENTSPLY Sirona, while arguably carrying a more discounted valuation and a dividend, has yet to demonstrate the durable catalysts needed to reverse its downtrend. Probabilistically, the weight of observable evidence—momentum, stability, and near-term catalysts—leans toward KIDS, though this assessment reflects current conditions rather than a guarantee of future performance. I’m watching this closely as conditions evolve.
Using Tickeron’s AI Tools in My Research
In my analysis of names like these, Tickeron’s AI Daily Buy/Sell Signals has proven helpful for confirming momentum shifts and generating rules-based ideas alongside traditional fundamentals. It allows me to cross-check trend consistency without relying solely on manual review, which adds a useful layer when comparing growth stories to turnarounds in the medical sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRAY's RSI Indicator ascending out of oversold territory
The RSI Oscillator for XRAY moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 30 of the 42 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 27 of 53 cases over the following month. The odds of a continued upward trend are 51%.
XRAY moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.436) is normal, around the industry mean (4.946). P/E Ratio (-3.564) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.066) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a global denal eqipment company
Industry PharmaceuticalsOther
Advertisement